Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Aberrant expression of Sec61α in esophageal cancers.

Bachmann K, Bockhorn M, Mann O, Gebauer F, Blessmann M, Izbicki JR, Grupp K.

J Cancer Res Clin Oncol. 2019 Jun 13. doi: 10.1007/s00432-019-02955-7. [Epub ahead of print]

PMID:
31197453
2.

Cholecystokinin-8 treatment reduces acinar necrosis and edema of pigs with induced pancreatitis.

Grupp K, Bonk S, Poppe A, Wodack K, Reeh M, Gocht A, Mann O, Izbicki JR, Bachmann K.

Asian J Surg. 2019 Jun 3. pii: S1015-9584(19)30013-2. doi: 10.1016/j.asjsur.2019.05.002. [Epub ahead of print]

3.

Melatonin treatment of pigs with acute pancreatitis reduces inflammatory reaction of pancreatic tissue and enhances fitness score of pigs: experimental research.

Grupp K, Erbes J, Poppe A, Wodack K, Gocht A, Trepte C, Havel J, Mann O, Izbicki JR, Bachmann K.

World J Emerg Surg. 2019 Apr 11;14:18. doi: 10.1186/s13017-019-0237-2. eCollection 2019.

4.

Separating Response of Tumor and non-Tumor Cells to Drug In Vitro by Quantifying a Mutation.

Kleinpoppen M, Moebius C, Grupp K, Kluwe L, Blessmann M.

Anticancer Res. 2019 Apr;39(4):1777-1783. doi: 10.21873/anticanres.13284.

PMID:
30952717
5.

p53 overexpression is a prognosticator of poor outcome in esophageal cancer.

Melling N, Norrenbrock S, Kluth M, Simon R, Hube-Magg C, Steurer S, Hinsch A, Burandt E, Jacobsen F, Wilczak W, Quaas A, Bockhorn M, Grupp K, Tachezy M, Izbicki J, Sauter G, Gebauer F.

Oncol Lett. 2019 Apr;17(4):3826-3834. doi: 10.3892/ol.2019.10020. Epub 2019 Feb 6.

6.

Decentralized colorectal cancer care in Germany over the last decade is associated with high in-hospital morbidity and mortality.

Ghadban T, Reeh M, Bockhorn M, Grotelueschen R, Bachmann K, Grupp K, Uzunoglu FG, Izbicki JR, Perez DR.

Cancer Manag Res. 2019 Mar 12;11:2101-2107. doi: 10.2147/CMAR.S197865. eCollection 2019.

7.

Increase of CD45-positive Immune Cells in Liver Parenchyma Indicates a More Favorable Prognosis for Patients With Barrett's Cancer.

Kemper M, Strohm T, Grupp K, Ghadban T, Bogoevski D, Bachmann K, Bockhorn M, Sauter G, Izbicki JR, Reeh M.

Anticancer Res. 2019 Mar;39(3):1191-1196. doi: 10.21873/anticanres.13229.

PMID:
30842149
8.

Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers.

Melling N, Bachmann K, Hofmann B, El Gammal AT, Reeh M, Mann O, Moebius C, Blessmann M, Izbicki JR, Grupp K.

J Cancer Res Clin Oncol. 2019 Apr;145(4):873-879. doi: 10.1007/s00432-019-02850-1. Epub 2019 Feb 13.

PMID:
30758670
9.

High levels of RAI3 expression is linked to shortened survival in esophageal cancer patients.

El Gammal AT, Melling N, Reeh M, Gebauer F, Mann O, Perez D, Bockhorn M, Bachmann K, Izbicki JR, Grupp K.

Exp Mol Pathol. 2019 Apr;107:51-56. doi: 10.1016/j.yexmp.2019.01.013. Epub 2019 Jan 29.

PMID:
30707896
10.

Duodenum-preserving pancreatic head resection: A retrospective analysis of the Hamburg Modification.

Bellon E, Roswora MD, Melling N, Grotelueschen R, Grupp K, Reeh M, Ghadban T, Izbicki JR, Bachmann K.

Surgery. 2019 May;165(5):938-945. doi: 10.1016/j.surg.2018.11.009. Epub 2019 Jan 15.

PMID:
30658850
11.

FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas.

Grupp K, Uzunoglu FG, Melling N, Hofmann B, El Gammal AT, Grotelüschen R, Heumann A, Bellon E, Reeh M, Wolters-Eisfeld G, Ghabdan T, Nentwich M, Bachmann K, Bockhorn M, Bogoevski D, Izbicki JR, Kutup A.

Sci Rep. 2018 Nov 26;8(1):17370. doi: 10.1038/s41598-018-35459-4.

12.

Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome.

Grupp K, Hofmann B, Kutup A, Bachmann K, Bogoevski D, Melling N, Uzunoglu FG, El Gammal AT, Koop C, Simon R, Steurer S, Krech T, Burdak-Rothkamm S, Jacobsen F, Sauter G, Izbicki J, Wilczak W.

BMC Cancer. 2018 Nov 12;18(1):1106. doi: 10.1186/s12885-018-5032-z.

13.

High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases.

Brandi F, Grupp K, Hube-Magg C, Kluth M, Lang D, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wittmer C, Jacobsen F, Huland H, Steurer S, Lebok P, Hinsch A, Wilczak W, Schlomm T, Simon R.

Oncol Lett. 2018 Nov;16(5):6238-6244. doi: 10.3892/ol.2018.9417. Epub 2018 Sep 7.

14.

Expression of ICAM-1, E-cadherin, periostin and midkine in metastases of pancreatic ductal adenocarcinomas.

Grupp K, Melling N, Bogoevska V, Reeh M, Uzunoglu FG, El Gammal AT, Nentwich MF, Izbicki JR, Bogoevski D.

Exp Mol Pathol. 2018 Apr;104(2):109-113. doi: 10.1016/j.yexmp.2018.01.005. Epub 2018 Feb 2.

PMID:
29355490
15.

High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.

Heumann A, Heinemann N, Hube-Magg C, Lang DS, Grupp K, Kluth M, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Wittmer C, Jacobsen F, Huland H, Simon R, Schlomm T, Sauter G, Steurer S, Lebok P, Hinsch A.

BMC Cancer. 2018 Jan 5;18(1):37. doi: 10.1186/s12885-017-3956-3.

16.

FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.

Tsourlakis MC, Eleftheriadou A, Stender A, Weigand P, Grupp K, Hube-Magg C, Kluth M, Schroeder C, Steurer S, Hinsch A, Luebke A, Angerer A, Wittmer C, Friedrich E, Göbel C, Büscheck F, Heinzer H, Graefen M, Simon R, Sauter G, Wilczak W, Minner S, Schlomm T, Jacobsen F.

Carcinogenesis. 2017 Dec 7;38(12):1180-1187. doi: 10.1093/carcin/bgx105.

PMID:
29029032
17.

Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.

Wilczak W, Rashed S, Hube-Magg C, Kluth M, Simon R, Büscheck F, Clauditz TS, Grupp K, Minner S, Tsourlakis MC, Möller-Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Izbicki JR, Huland H, Schlomm T, Steurer S, Krech T, Lebok P.

Carcinogenesis. 2017 Jan;38(1):19-27. doi: 10.1093/carcin/bgw116. Epub 2016 Nov 1.

PMID:
27803051
18.

Microvascular stent anastomosis using N-fibroin stents: feasibility, ischemia time, and complications.

Smeets R, Vorwig O, Wöltje M, Gaudin R, Luebke AM, Beck-Broichsitter B, Rheinnecker M, Heiland M, Grupp K, Gröbe A, Hanken H.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 May;121(5):e97-e103. doi: 10.1016/j.oooo.2016.01.009. Epub 2016 Jan 21. Erratum in: Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Nov;122(5):657.

PMID:
27068318
19.

Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.

Grupp K, Roettger L, Kluth M, Hube-Magg C, Simon R, Lebok P, Minner S, Tsourlakis MC, Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Wilczak W, Huland H, Schlomm T, Steurer S, Krech T.

Oncol Rep. 2015 Sep;34(3):1211-20. doi: 10.3892/or.2015.4080. Epub 2015 Jun 25.

PMID:
26134445
20.

COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.

Hofmann BT, Schlüter L, Lange P, Mercanoglu B, Ewald F, Fölster A, Picksak AS, Harder S, El Gammal AT, Grupp K, Güngör C, Drenckhan A, Schlüter H, Wagener C, Izbicki JR, Jücker M, Bockhorn M, Wolters-Eisfeld G.

Mol Cancer. 2015 May 29;14:109. doi: 10.1186/s12943-015-0386-1.

Supplemental Content

Loading ...
Support Center